Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SOG8
|
|||
| Drug Name |
NBM-BMX
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
NatureWise Biotech & Medicals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase 8 (HDAC8) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Alcoholism | |||
| Viral carcinogenesis | ||||
| Panther Pathway | Wnt signaling pathway | |||
| Pathway Interaction Database | Signaling events mediated by HDAC Class I | |||
| Reactome | NOTCH1 Intracellular Domain Regulates Transcription | |||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| HDACs deacetylate histones | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| Neural Crest Differentiation | ||||
| Cell Cycle | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03808870) A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.